We are excited to announce the closing of our €8 million Series A funding round that will enable us to accelerate the development of new applications of our patented UV-free antimicrobial technology Biovitae: an innovative solution for continuous air and surface sanitization.
The round consisted of two tranches:
– €3 million subscribed by Angelini Investments in November 2023
– €5 million raised in March 2025 thanks to Fondazione EneaTech & Biomedical (€4M) and a follow-on from Angelini Investments (€1M)
This investment is not only an important financial support, but also a concrete recognition of the value of our project and the impact that Biovitae can have in the field of Infection Prevention and Control (IPC) and antimicrobial resistance (AMR), fully consistent with the OneHealth paradigm.
Over the past year we:
✅ Expanded Biovitae’s applications to strategic sectors: healthcare, education, fitness, food industry, home appliances and transportation
✅ Strengthened our R&D for antimicrobial LED innovation
✅ Started collaborations for our future international expansion
With the new resources, we will continue to scale up Biovitae, expanding production capacity and taking our technology to a global reach.
Sincere thanks to our investors, partners and the entire Nextsense team.
We are just getting started
